RG
RGC.US Regencell Bioscience Holdings Ltd
- Market cap
- USD 2.34B
- P/E
- -
- P/B
- 182.39x
- ROE
- -191.3%
- Dividend yield
- -
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 1 quarter up to Sep 2026.
Is RGC.US undervalued?
Graham numberThe Graham number of Regencell Bioscience Holdings Ltd cannot be estimated reliably (it needs positive earnings and book value).
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Regencell Bioscience Holdings Ltd fundamental analysis
No fundamental analysis for Regencell Bioscience Holdings Ltd yet.
Regencell Bioscience Holdings Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Full company profileRegencell Bioscience Holdings Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 1 quarter up to Sep 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Regencell Bioscience Holdings Ltd annual financial statements (USD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||
| Revenue | 3.20B | 3.16B | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | - | 0.00 | - |
| Gross Profit | 1.97B | 3.04B | - | -9.52K | -26.5K | -604K | -770K | -746K | -393K | -405K | -1.45M |
| Operating Income | 344M | 272M | -391K | -812K | -1.38M | -7.62M | -6.27M | -4.74M | -3.77M | -11.7M | -25.5M |
| EBITDA | 512M | 469M | -391K | -803K | -1.35M | -6.99M | -5.29M | -3.62M | -3.19M | -11.3M | -24.1M |
| Net Income | 170M | 112M | -391K | -812K | -1.35M | -7.42M | -5.87M | -4.30M | -3.58M | -11.7M | -25.5M |
| EPS | 0.03 | 0.02 | 0.00 | 0.00 | 0.00 | -0.02 | -0.01 | -0.01 | -0.01 | -0.02 | -0.05 |
| Balance Sheet | |||||||||||
| Total Assets | 2.65B | 2.84B | 243K | 514K | 340K | 18.0M | 12.6M | 8.44M | 5.76M | 14.7M | 14.7M |
| Total Liabilities | 3.48B | 3.70B | 2.08M | 3.16M | 4.34M | 938K | 632K | 220K | 895K | 1.38M | 1.38M |
| Shareholders' Equity | -839M | -856M | -1.84M | -2.65M | -4.00M | 17.1M | 12.0M | 8.22M | 4.86M | 13.3M | 13.3M |
| Cash & Short-term Investments | 247M | 229M | 243K | 387K | 59.4K | 16.4M | 11.6M | 7.96M | 4.90M | 14.2M | 14.2M |
| Total Debt | 2.22B | 2.37B | 2.08M | 3.07M | 3.68M | 771K | 464K | 85.7K | 544K | 296K | 296K |
| Cash Flow | |||||||||||
| Operating Cash Flow | 411M | 410M | -391K | -727K | -767K | -5.27M | -4.96M | -4.00M | -3.11M | -7.70M | -20.4M |
| Capital Expenditure | 215M | 250M | 118K | 118K | 1.00 | 781K | 27.4K | 5.38K | 153K | 0.00 | 0.00 |
| Free Cash Flow | 196M | 160M | -391K | -844K | -767K | -6.05M | -4.99M | -4.01M | -3.27M | -7.70M | -20.4M |
| Ratios | |||||||||||
| ROE | - | - | - | - | - | -43.5% | -48.8% | -52.3% | -73.7% | -87.7% | -191.3% |
| ROA | 6.4% | 4.0% | -160.7% | -158.0% | -395.9% | -41.2% | -46.5% | -51.0% | -62.3% | -79.4% | -173.4% |
| Net Profit Margin | 5.3% | 3.6% | - | - | - | - | - | - | - | - | - |
| Debt to Equity | - | - | - | - | - | 0.05x | 0.04x | 0.01x | 0.11x | 0.02x | 0.02x |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Regencell Bioscience Holdings Ltd dividends
- Dividend yield
- -
- Forward dividend
- -
- Payout ratio
- -
- Ex-dividend date
- -
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2026 | - | - | - |
| 2025 | - | - | - |
| 2024 | - | - | - |
| 2023 | - | - | - |
| 2022 | - | - | - |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | USD 139M | 0.02 | 123.7% |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 38:1 on Jun 16, 2025.
Who owns Regencell Bioscience Holdings Ltd
- Insiders 88.55%
- Institutions 0.20%
- Public & others 11.26%
- Shares outstanding 496M
- Free float 55.6M
Top funds holding RGC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Fidelity Nasdaq Composite Index | 302K | 0.06% | 0.00% | Aug 2026 |
| Fidelity Nasdaq Composite ETF | 123K | 0.02% | 0.00% | Oct 2026 |
| CIBC US Broad Market Index | 15.3K | 0.00% | 0.00% | Aug 2026 |
| JHVIT Total Stock Market Index I | 7.65K | 0.00% | 0.00% | Sep 2026 |
| undrly FID DCL&G LwCarbTrnstnGlbEqUnHOFC | 6.76K | 0.00% | -2.80% | Sep 2026 |
| L&G FW Tilte& Opt Dev FS FU Ex Idx L ACC | 4.09K | 0.00% | 0.00% | Sep 2026 |
| State Street® SPDR® S&P® China ETF | 4.05K | 0.00% | 0.00% | Oct 2026 |
| FID DC L&G Retirement Income MA Fund | 3.76K | 0.00% | +3.70% | Sep 2026 |
| L&G Fut WldESGTilted&OptdAsiaPacIdxL£Acc | 3.20K | 0.00% | 0.00% | Jul 2026 |
| Scotia International Equity Tracker ETF | 1.90K | 0.00% | 0.00% | Jul 2026 |
| Undly L&G Fut Wld Dev (ex UK) Eq Idx Fd | 1.11K | 0.00% | -11.31% | Sep 2026 |
| KraneShares ICBCUBS S&P China 500 ETF$ | 678.00 | 0.00% | 0.00% | Oct 2026 |
| Scotia International Equity Index A | 300.00 | 0.00% | 0.00% | Jul 2026 |
Top institutions holding RGC.US
| Holder | Shares | % of shares | Change | As of |
|---|---|---|---|---|
| Geode Capital Management, LLC | 422K | 0.09% | +1.55% | Jun 2026 |
| Alyeska Investment Group, L.P. | 416K | 0.08% | 0.00% | Jun 2026 |
| Legal & General Group PLC | 128K | 0.03% | +1,192.54% | Jun 2026 |
| Jane Street Group LLC | 98.3K | 0.02% | 0.00% | Jun 2026 |
| XTX Topco Ltd | 60.1K | 0.01% | 0.00% | Jun 2026 |
| Amundi | 47.2K | 0.01% | +448.68% | Jun 2026 |
| UBS Group AG | 43.2K | 0.01% | +80.90% | Jun 2026 |
| Quadrature Capital Limited | 41.8K | 0.01% | 0.00% | Jun 2026 |
| Susquehanna International Group, LLP | 23.1K | 0.00% | 0.00% | Jun 2026 |
| Squarepoint Ops LLC | 22.0K | 0.00% | -17.20% | Jun 2026 |
| Fox Run Management LLC | 20.7K | 0.00% | 0.00% | Jun 2026 |
| CIBC Global Asset Management Inc | 15.3K | 0.00% | 0.00% | Jun 2026 |
| Bank of America Corp | 15.0K | 0.00% | -12.68% | Jun 2026 |
| Two Sigma Investments LLC | 14.4K | 0.00% | 0.00% | Jun 2026 |
| Vident Advisory, LLC | 11.2K | 0.00% | -62.15% | Jun 2026 |
| Morgan Stanley - Brokerage Accounts | 5.05K | 0.00% | -74.84% | Jun 2026 |
| BlackRock Inc | 4.93K | 0.00% | -0.65% | Jun 2026 |
| State of Wyoming | 4.07K | 0.00% | 0.00% | Jun 2026 |
| Federation des caisses Desjardins du Quebec | 2.80K | 0.00% | +25.64% | Jun 2026 |
| Aquatic Capital Management LLC | 2.06K | 0.00% | 0.00% | Jun 2026 |
Regencell Bioscience Holdings Ltd company profile
- Company name
- Regencell Bioscience Holdings Ltd
- Ticker
- RGC.US
- ISIN
- KYG7487R1002
- Exchange
- USA Stocks
- Listed since
- Jul 16, 2021
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 10
- Fiscal year end
- June
- Address
- Chinachem Leighton Plaza, Causeway Bay, Hong Kong
- Phone
- 852 2155 0823
- Website
- regencellbioscience.com
About Regencell Bioscience Holdings Ltd
Regencell Bioscience Holdings Limited focuses on the research, development, and commercialization of Traditional Chinese Medicine (TCM) in Hong Kong. It focuses on the research, development, and commercialization of TCM for the treatment of neurocognitive disorders and degeneration, TCM brain theory, primarily for attention deficit hyperactivity disorder and autism spectrum disorder. The company was incorporated in 2014 and is headquartered in Causeway Bay, Hong Kong.
Regencell Bioscience Holdings Ltd management
5- Mr. Yat-Gai AuFounder, Chairman & CEO · born 1973
- Ms. Michelle ChanFinancial Controller, CFO & Principal Financial Officer
- Mr. Wai Hong ChungCOO, Chief Strategy Officer & Director · born 1978
- Ms. Antonia AssangSenior Vice President of Project Management
- Mr. Yat-Pui AuChief Business Officer · born 1975